KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Investments (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 11 years of Long-Term Investments data on record, last reported at $1.0 billion in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 81.03% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 81.03%, while the annual FY2025 figure was $1.0 billion, 81.03% up from the prior year.
  • Long-Term Investments reached $1.0 billion in Q4 2025 per JAZZ's latest filing, up from $720.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.0 billion in Q4 2025 and bottomed at $60.0 million in Q2 2022.
  • Average Long-Term Investments over 5 years is $417.5 million, with a median of $387.5 million recorded in 2024.
  • Peak YoY movement for Long-Term Investments: soared 681.25% in 2024, then fell 23.2% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $335.0 million in 2021, then tumbled by 82.09% to $60.0 million in 2022, then soared by 100.0% to $120.0 million in 2023, then surged by 383.33% to $580.0 million in 2024, then soared by 81.03% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $1.0 billion in Q4 2025, $720.0 million in Q3 2025, and $480.0 million in Q2 2025.